Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
1Customers
3Debt Items
12Related Chains
Source-Backed Evidence Depth
Brainstorm Cell Therapeutics Inc. (BCLI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
2Distinct source URLs
6High confidence
0.818Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Brainstorm Cell Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
RAMOT
RAMOT
90%
Under this agreement, our Israeli subsidiary pays royalties to Ramot ranging between three percent (3%) and five percent (5%) of all net sales derived from the licensed intellectual property
SUPPLIER
SUPPLIER
90%
During the reporting period, the Company settled outstanding accounts payable to a supplier in the amount of $ 450 through the issuance of 281,250 shares of common stock.
Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX g…
Reciprocal relationship from NCEL graph: ens the development time nor regulatory review time of a drug nor does it increase the likelihood for any approval in the regulatory review process. Sponsors …
Brainstorm Cell Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
GENESIS-HEALTHCARE-INC
GENESIS-HEALTHCARE-INC
62%
nts. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial cost. Healthcare reform A primary trend i…
Brainstorm Cell Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BCLI-DEBT-8102
Warrants outstanding: 250000
90%
xbrl warrant detail from xbrl 2025-12-31.
BCLI-DEBT-8103
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-12-31.
BCLI-DEBT
Debt stack $1.3M
90%
Market cache reports total debt of $1.3M.
Brainstorm Cell Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Brainstorm Cell Therapeutics Inc..
Brainstorm Cell Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
BCLI-OWNER-OSAIC-HOLDINGS-INC
OSAIC HOLDINGS, INC.
90%
13F overlay lists OSAIC HOLDINGS, INC. as top holder; 5 tracked holders.
Brainstorm Cell Therapeutics Inc. Extended Supply Chain Network
